News from Zentiva
STEFFEN SALTOFTE APPOINTED AS CEO OF ZENTIVA
Zentiva is pleased to announce the appointment of Steffen Saltofte to the role of Chief Executive Officer (CEO), succeeding Nick Haggar who moves to the Zentiva Advisory Committee as a non-executive member. Steffen joins as CEO with effect from 2nd May 2023.
Steffen Saltofte joins from Acino, where he was CEO from 2018 until 2022. He brings a wealth of strategic and operational experience from large multinationals and fast growing companies, and will lead the further acceleration of Zentiva. Steffen will be based in Prague.
Steffen Saltofte commented: “I am excited to be joining Zentiva, a company with a strong track record in business growth and customer focus. Together we will continue this growth story, bringing high-quality affordable medicines to people across Europe and beyond. Health and access to medicines are more important than ever and I am fully committed to Zentiva’s mission.”
The Zentiva Advisory Committee, shareholders and employees wish to thank Nick Haggar for his leadership during the last four years as CEO. Nick’s vision, inspiration and drive to create a high performing, inclusive and sustainable European pharmaceutical company has helped Zentiva double in size over the last four years. Nick will join the Zentiva Advisory Committee and is excited to support future development of the Company as a non-executive.
More than 100 million people trust Zentiva medicines to help them with their medical conditions and healthcare every year.